LEHI, Utah / Feb 26, 2025 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, announced today that it will participate in TD Cowen's 45th Annual Health Care Conference on March 5, 2025 at the Boston Marriott Copley Place. Kurt Workman, Owlet’s Chief Executive Officer and Co-Founder, Jonathan Harris, President and Chief Revenue Officer, and Amanda Twede-Crawford, Chief Financial Officer, are scheduled to engage in a fireside chat on Wednesday, March 5, 2025, at 9:50 a.m. ET.
A link to the live webcast of the fireside chat will be available on the Owlet Investor Relations website, investors.owletcare.com. A replay of the webcast will also be available on Owlet’s Investor Relations website.
About Owlet, Inc.
Owlet’s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE: OWLT), a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.
Since 2012, over two million parents worldwide have used Owlet’s platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life.
To learn more, visit www.owletcare.com.
| Last Trade: | US$14.35 |
| Daily Change: | -0.57 -3.82 |
| Daily Volume: | 222,173 |
| Market Cap: | US$395.770M |
December 18, 2025 December 10, 2025 November 25, 2025 November 19, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load